The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment
Open accessAbstract
Importance: Most cognitive functions decline with age. Prior studies suggest that testosterone treatment may improve these functions. Objective: To determine if testosterone treatment compared with placebo is associated with improved verbal memory and other cognitive functions in older men with low testosterone and age-associated memory impairment (AAMI). Design, Setting, and Participants: The Testosterone Trials (TTrials) were 7 trials to assess the efficacy of testosterone treatment in older men with low testosterone levels. The Cognitive Function Trial evaluated cognitive function in all TTrials participants. In 12 US academic medical centers, 788 men who were 65 years or older with a serum testosterone level less than 275 ng/mL and impaired sexual function, physical function, or vitality were allocated to testosterone treatment (n = 394) or placebo (n = 394). A subgroup of 493 men met criteria for AAMI based on baseline subjective memory complaints and objective memory performance. Enrollment in the TTrials began June 24, 2010; the final participant completed treatment and assessment in June 2014. Interventions: Testosterone gel (adjusted to maintain the testosterone level within the normal range for young men) or placebo gel for 1 year. Main Outcomes and Measures: The primary outcome was the mean change from baseline to 6 months and 12 months for delayed paragraph recall (score range, 0 to 50) among men with AAMI. Secondary outcomes were mean changes in visual memory (Benton Visual Retention Test; score range, 0 to -26), executive function (Trail-Making Test B minus A; range, -290 to 290), and spatial ability (Card Rotation Test; score range, -80 to 80) among men with AAMI. Tests were administered at baseline, 6 months, and 12 months. Results: Among the 493 men with AAMI (mean age, 72.3 years [SD, 5.8]; mean baseline testosterone, 234 ng/dL [SD, 65.1]), 247 were assigned to receive testosterone and 246 to receive placebo. Of these groups, 247 men in the testosterone group and 245 men in the placebo completed the memory study. There was no significant mean change from baseline to 6 and 12 months in delayed paragraph recall score among men with AAMI in the testosterone and placebo groups (adjusted estimated difference, -0.07 [95% CI, -0.92 to 0.79]; P = .88). Mean scores for delayed paragraph recall were 14.0 at baseline, 16.0 at 6 months, and 16.2 at 12 months in the testosterone group and 14.4 at baseline, 16.0 at 6 months, and 16.5 at 12 months in the placebo group. Testosterone was also not associated with significant differences in visual memory (-0.28 [95% CI, -0.76 to 0.19]; P = .24), executive function (-5.51 [95% CI, -12.91 to 1.88]; P = .14), or spatial ability (-0.12 [95% CI, -1.89 to 1.65]; P = .89). Conclusions and Relevance: Among older men with low testosterone and age-associated memory impairment, treatment with testosterone for 1 year compared with placebo was not associated with improved memory or other cognitive functions. Trial Registration: clinicaltrials.gov Identifier: NCT00799617.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Though testosterone therapy improves bone mineral density, lean body mass, erectile function, and anemia, there is inconclusive evidence on the benefits of testosterone therapy on cognitive function, energy levels, blood glucose or lipid levels, and controversy remains around whether testosterone therapy affects the risk of cardiovascular events (6-13).”
From Non-testosterone management of male hypogonadism: an examination of the existing literature (2020) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Though testosterone therapy improves bone mineral density, lean body mass, erectile function, and anemia, there is inconclusive evidence on the benefits of testosterone therapy on cognitive function, energy levels, blood glucose or lipid levels, and controversy remains around whether testosterone therapy affects the risk of cardiovascular events (6-13).”
From Non-testosterone management of male hypogonadism: an examination of the existing literature (2020) · cites this paper as [9]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Though testosterone therapy improves bone mineral density, lean body mass, erectile function, and anemia, there is inconclusive evidence on the benefits of testosterone therapy on cognitive function, energy levels, blood glucose or lipid levels, and controversy remains around whether testosterone therapy affects the risk of cardiovascular events (6-13).”
From Non-testosterone management of male hypogonadism: an examination of the existing literature (2020) · cites this paper as [9]
Experimental — accuracy not yet measuredIn the citing paper
“However, some groups have shown that T replacement in old men does not provide significant benefits in strength 214-217 or cognition,218 increases coronary artery plaque formation,219 and is consistently shown to have no effect on insulin sensitivity.216, 220”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [218]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Peter, H., Penzel, T., Peter, J. H., & Peter, J. G. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_302294 · Cited by 2,278
Models of visuospatial and verbal memory across the adult life span.
Park, D. C., Lautenschlager, G. J., Hedden, T., Davidson, N. S., Smith, A. D., & Smith, P. K. (2002) · Psychology and Aging · doi:10.1037/0882-7974.17.2.299 · Cited by 1,929
Feldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., & McKinlay, J. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8201 · Cited by 1,861
Monitoring Depression Treatment Outcomes With the Patient Health Questionnaire-9
L??we, B., Un??tzer, J., Callahan, C. M., Perkins, A. J., & Kroenke, K. (2004) · Medical Care · doi:10.1097/00005650-200412000-00006 · Cited by 1,354
Crook, T. H., Bartus, R. T., Ferris, S. H., Whitehouse, P. J., Cohen, G. D., & Gershon, S. (1986) · Developmental Neuropsychology · doi:10.1080/87565648609540348 · Cited by 930
Minimization: A new method of assigning patients to treatment and control groups
Taves, D. R. (1974) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1974155443 · Cited by 891
Effects of Testosterone Treatment in Older Men
Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., Gill, T. M., Barrett-Connor, E., Swerdloff, R. S., Wang, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506119 · Cited by 890
Self-citationThe A4 Study: Stopping AD Before Symptoms Begin?
Sperling, R. A., Rentz, D. M., Johnson, K. A., Karlawish, J. H., Donohue, M., Salmon, D. P., & Aisen, P. S. S. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007941 · Cited by 778
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–220 of 220
Endocrine Factors Related to Frailty
Urano, T. (2022) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.111.618
Hypogonadismus, Infertilität und sexuelle Dysfunktion bei systemischen Erkrankungen
Sartorius, G. A., & Handelsman, D. J. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-61901-8_34
Male Hypogonadism and Aging: An Update
Iglesias, P., Núñez, A., & Díez, J. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-31501-5_9
Psychological effects of testosterone
Huhtaniemi, I. T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13432-6.00001-0
Advances in Research Related to Post-Stroke Sarcopenia
陈, 晓. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.143808
Ratnakaran, B., Jan, D., Raelly-Muze, L., Owens, T., & Wang, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-55711-8_7
Hypogonadism and testosterone therapy in elderly men
Yeap, B. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00046-7
Männlicher Hypogonadismus und Alterung: ein Update
Iglesias, P., Núñez, A., & Díez, J. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-65245-5_9
Reproductive and nonreproductive actions of testosterone
Gagliano‐Jucá, T., Jain, A., Jasuja, R., & Bhasin, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00198-9
Self-citationHormone replacement therapy, male
Wang, C., & Swerdloff, R. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00263-6
Self-citationTestosterone Therapy in Men with Functional Hypogonadism
Mauvais‐Jarvis, F. (2025) · Springer eBooks · doi:10.1007/978-3-031-89650-7_15
History of Testosterone Therapy in Men with Testosterone Deficiency: 1939–2024
Traish, A. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-89650-7_14
Testosterone Replacement Therapy
Amory, J. K., & Amory, T. G. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_18
Testosterone Measurement, Use and Misuse
Handelsman, D. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_17
The influence of sex steroids on cognition in elderly men
Caetano, C. D. C. B., Liberman, S., Ie, J. M. L., Toscano, V. C. A., Jacob, W., & Bachega, T. A. S. S. (2026) · Clinics · doi:10.1016/j.clinsp.2026.100892
Vascular Involvement in Cognitive Impairment: Sex Differences
Griffin, A., Bhopatkar, A. A., Butler, K. R., Williams, J. M., Hinton, A., & Wallace, K. L. (2026) · Physiology in health and disease · doi:10.1007/978-3-032-26472-5_23
Malich, D., & Vasylyshyn, A. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1901486
Key findings on the efficacy and safety of testosterone therapy from two large randomized trials
Braga, M., & Basaria, S. S. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag397
Self-citationUpdate on testosterone deficiency and therapeutic options for testosterone replacement therapy
Thompson, T., Mubarak, M., Jones, T. H., Pearce, I., & Modgil, V. (2026) · Nature Reviews Urology · doi:10.1038/s41585-026-01190-3
Male hypogonadism in general practice: from risk factors to testosterone therapy
Fontana, M., & Broul, M. (2026) · Medicína pro praxi · doi:10.36290/med.2026.034
Metadata
- Authors
- Resnick, S. M., Matsumoto, A. M., Stephens-Shields, A. J., Ellenberg, S. S., Gill, T. M., Shumaker, S. A., Pleasants, D. D., Barrett-Connor, E., Bhasin, S., Cauley, J. A., Cella, D., Crandall, J. P., Cunningham, G. R., Ensrud, K. E., Farrar, J. T., Lewis, C. E., Molitch, M. E., Pahor, M., Swerdloff, R. S., Cifelli, D., Anton, S., Basaria, S., Diem, S. J., Wang, C., Hou, X., & Snyder, P. J.
- Affiliations
- National Institutes of Health (US)
- University of Washington (US)
- Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia
- University of Pennsylvania (US)
- Yale University (US)
- Wake Forest University Health Sciences (US)
- University of California San Diego (US)
- Brigham and Women's Hospital (US)
- University of Pittsburgh (US)
- Northwestern University (US)
- Albert Einstein College of Medicine (US)
- University of Minnesota (US)
- University of Alabama at Birmingham (US)
- University of Florida (US)
- University of California, Los Angeles (US)
- Corresponding author
- Snyder, Peter J.
- ORCID
- Resnick, Susan M.
- Matsumoto, Alvin M.
- Ellenberg, Susan S.
- Gill, Thomas M.
- Barrett-Connor, Elizabeth
- Bhasin, Shalender
- Cauley, Jane A.
- Cella, David
- Crandall, Jill P.
- Cunningham, Glenn R.
- Ensrud, Kristine E.
- Farrar, John T.
- Lewis, Cora E.
- Molitch, Mark E.
- Swerdloff, Ronald S.
- Anton, Stephen
- Basaria, Shehzad
- Diem, Susan J.
- Wang, Christina
- Hou, Xiaoling
- Snyder, Peter J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2017-02-21
- Volume
- 317
- Issue
- 7
- Pages
- 717
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC5433758
- OpenAlex
- W2594566853
- Cited by
- 220
- References
- 36
- Citations by year
- 2026: 9 · 2025: 20 · 2024: 17 · 2023: 18 · 2022: 23 · 2021: 24 · 2020: 27 · 2019: 27 · 2018: 30 · 2017: 25
- FWCI
- 23.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5p60dk079626-05, UL1TR000142, 5p30ag031679-15)
- National Institute on Aging (U01AG030644, R01AG037679, K07AG043587, P30-AG031679, P30AG028740, P30AG021342)
- National Institute of Diabetes and Digestive and Kidney Diseases (P60-DK-079626, P30DK020541, P30DK079626)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- testosterone replacement therapy, androgen deficiency, age-associated memory impairment, cognitive function, verbal memory, older men, testosterone gel, delayed recall, visual memory, executive function, spatial ability, subjective memory complaints, physical function, vitality, hormone replacement therapy
- MeSH terms
- Aged, Androgens, Cognition, Double-Blind Method, Gels, Humans, Male, Memory, Memory Disorders, Mental Recall, Reference Values, Testosterone, Time Factors, Treatment Outcome, Executive Function, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
